Journal of Clinical Oncology, Vol 20, Issue 3
(February), 2002: 850-856
© 2002 American Society for Clinical Oncology
Prospective Evaluation of the Peptide-Bound Collagen Type I Cross-Links N-Telopeptide and C-Telopeptide in Predicting Bone Metastases Status
By Luis Costa,
Laurence M. Demers,
A. Gouveia-Oliveira,
J. Schaller,
Eduardo B. Costa,
Miguel C. de Moura,
Allan Lipton
From the Hospital de Santa Maria, Faculdade de Medicina de Lisboa, Lisbon, Portugal; Milton S. Hershey Medical Center, Penn State University, Hershey, PA; and Department of Biometry and Epidemiology, Medical University of South Carolina, Charleston, SC.
Address reprint requests to Luis Costa, Unidade de Oncologia, Hospital de Santa Maria, Av Professor Egas Moniz, 1649-035 Lisbon, Portugal; email: luiscosta.p{at}mail.telepac.pt
PURPOSE: The objective assessment of bone metastases is currently based on serial changes in skeletal survey. We performed a prospective study to determine whether a correlation exists between the biochemical markers of bone turnover and x-ray evaluation of bone metastases in patients with or without bisphosphonate therapy, and whether bone markers are influenced by extraskeletal disease.
PATIENTS AND METHODS: Patients with either bone or extraskeletal metastases were consecutively enrolled and World Health Organization response criteria were applied for both bone and extraosseous disease every 3 to 4 months. Serum levels of bone-specific alkaline phosphatase (B-AP) and C-telopeptide (ICTP) and urine levels of N-telopeptide (NTX) were measured monthly. The data were analyzed by generalized estimation equation regression.
RESULTS: We studied 97 patients with bone metastases (52 also with extraskeletal metastases) and 26 with extraosseous disease only. Median time on study was 153 days, and 281 objective evaluations (171 in bone) were performed. With bisphosphonates (49 patients receiving pamidronate and three receiving clodronate), percent change from levels without therapy was 47% for NTX (P < .001) and 69% for B-AP (P = .008). With disease progression in bone, percent change from mean levels during stable disease was 152% for NTX (P < .001) and 144% for ICTP (P < .001) regardless of bisphosphonate therapy. NTX had the highest positive predictive value (71%) for the diagnosis of bone metastases progression. Extraskeletal disease had no significant effect on bone markers.
CONCLUSION: Urinary NTX may be a valuable bone marker to assess the antiresorptive effect of bisphosphonate therapy and to evaluate the progression of bone metastases.
 CiteULike  Complore  Connotea  Del.icio.us  Digg  Facebook  Reddit  Technorati  Twitter What's this?
This article has been cited by other articles:
|
|
|
|
 
J. Bickels, S. Dadia, and Z. Lidar
Surgical Management of Metastatic Bone Disease
J. Bone Joint Surg. Am.,
June 1, 2009;
91(6):
1503 - 1516.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Fizazi, A. Lipton, X. Mariette, J.-J. Body, Y. Rahim, J. R. Gralow, G. Gao, L. Wu, W. Sohn, and S. Jun
Randomized Phase II Trial of Denosumab in Patients With Bone Metastases From Prostate Cancer, Breast Cancer, or Other Neoplasms After Intravenous Bisphosphonates
J. Clin. Oncol.,
April 1, 2009;
27(10):
1564 - 1571.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Lipton, G. G. Steger, J. Figueroa, C. Alvarado, P. Solal-Celigny, J. J. Body, R. de Boer, R. Berardi, P. Gascon, K. S. Tonkin, et al.
Extended Efficacy and Safety of Denosumab in Breast Cancer Patients with Bone Metastases Not Receiving Prior Bisphosphonate Therapy
Clin. Cancer Res.,
October 15, 2008;
14(20):
6690 - 6696.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. G. Schwartz
Prostate Cancer, Serum Parathyroid Hormone, and the Progression of Skeletal Metastases
Cancer Epidemiol. Biomarkers Prev.,
March 1, 2008;
17(3):
478 - 483.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Lipton, G. G. Steger, J. Figueroa, C. Alvarado, P. Solal-Celigny, J.-J. Body, R. de Boer, R. Berardi, P. Gascon, K. S. Tonkin, et al.
Randomized Active-Controlled Phase II Study of Denosumab Efficacy and Safety in Patients With Breast Cancer-Related Bone Metastases
J. Clin. Oncol.,
October 1, 2007;
25(28):
4431 - 4437.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Lipton, R. J. Cook, P. Major, M. R. Smith, and R. E. Coleman
Zoledronic Acid and Survival in Breast Cancer Patients with Bone Metastases and Elevated Markers of Osteoclast Activity
Oncologist,
September 1, 2007;
12(9):
1035 - 1043.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J.-J. Body
Breast cancer: bisphosphonate therapy for metastatic bone disease.
Clin. Cancer Res.,
October 15, 2006;
12(20):
6258s - 6263s.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. J. Leeming, M. Koizumi, I. Byrjalsen, B. Li, P. Qvist, and L. B. Tanko
The Relative Use of Eight Collagenous and Noncollagenous Markers for Diagnosis of Skeletal Metastases in Breast, Prostate, or Lung Cancer Patients
Cancer Epidemiol. Biomarkers Prev.,
January 1, 2006;
15(1):
32 - 38.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. G. Schwartz, M. C. Hall, D. Stindt, S. Patton, J. Lovato, and F. M. Torti
Phase I/II Study of 19-nor-1{alpha}-25-Dihydroxyvitamin D2 (Paricalcitol) in Advanced, Androgen-Insensitive Prostate Cancer
Clin. Cancer Res.,
December 15, 2005;
11(24):
8680 - 8685.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G A Clines and T A Guise
Hypercalcaemia of malignancy and basic research on mechanisms responsible for osteolytic and osteoblastic metastasis to bone
Endocr. Relat. Cancer,
September 1, 2005;
12(3):
549 - 583.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. van der Pluijm, I. Que, B. Sijmons, J. T. Buijs, C. W.G.M. Lowik, A. Wetterwald, G. N. Thalmann, S. E. Papapoulos, and M. G. Cecchini
Interference with the Microenvironmental Support Impairs the De novo Formation of Bone Metastases In vivo
Cancer Res.,
September 1, 2005;
65(17):
7682 - 7690.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. E. Coleman, P. Major, A. Lipton, J. E. Brown, K.-A. Lee, M. Smith, F. Saad, M. Zheng, Y. J. Hei, J. Seaman, et al.
Predictive Value of Bone Resorption and Formation Markers in Cancer Patients With Bone Metastases Receiving the Bisphosphonate Zoledronic Acid
J. Clin. Oncol.,
August 1, 2005;
23(22):
4925 - 4935.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. E. Brown, R. J. Cook, P. Major, A. Lipton, F. Saad, M. Smith, K.-A. Lee, M. Zheng, Y.-J. Hei, and R. E. Coleman
Bone Turnover Markers as Predictors of Skeletal Complications in Prostate Cancer, Lung Cancer, and Other Solid Tumors
J Natl Cancer Inst,
January 5, 2005;
97(1):
59 - 69.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. D. Roodman
Mechanisms of Bone Metastasis
N. Engl. J. Med.,
April 15, 2004;
350(16):
1655 - 1664.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. D. Michaelson, R. M. Marujo, and M. R. Smith
Contribution of Androgen Deprivation Therapy to Elevated Osteoclast Activity in Men with Metastatic Prostate Cancer
Clin. Cancer Res.,
April 15, 2004;
10(8):
2705 - 2708.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Fohr, C. R. Dunstan, and M. J. Seibel
Markers of Bone Remodeling in Metastatic Bone Disease
J. Clin. Endocrinol. Metab.,
November 1, 2003;
88(11):
5059 - 5075.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. E. Hillner, J. N. Ingle, R. T. Chlebowski, J. Gralow, G. C. Yee, N. A. Janjan, J. A. Cauley, B. A. Blumenstein, K. S. Albain, A. Lipton, et al.
American Society of Clinical Oncology 2003 Update on the Role of Bisphosphonates and Bone Health Issues in Women With Breast Cancer
J. Clin. Oncol.,
November 1, 2003;
21(21):
4042 - 4057.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. L. Weber and M. C. Gebhardt
What's New in Musculoskeletal Oncology
J. Bone Joint Surg. Am.,
March 31, 2003;
85(4):
761 - 767.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M.-F. Hou, S.-B. Lin, S.-S. F. Yuan, L.-Y. Tsai, S.-M. Tsai, J.-S. Hsieh, and T.-J. Huang
Diagnostic Value of Urine Deoxypyridinoline for Detecting Bone Metastases in Breast Cancer Patients
Ann. Clin. Lab. Sci.,
January 1, 2003;
33(1):
55 - 61.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
